A detailed history of Parkside Financial Bank & Trust transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Parkside Financial Bank & Trust holds 879 shares of VKTX stock, worth $57,899. This represents 0.01% of its overall portfolio holdings.

Number of Shares
879
Previous 874 0.57%
Holding current value
$57,899
Previous $46,000 19.57%
% of portfolio
0.01%
Previous 0.01%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 07, 2024

BUY
$49.84 - $70.47 $249 - $352
5 Added 0.57%
879 $55,000
Q2 2024

Aug 05, 2024

BUY
$47.39 - $80.2 $1,848 - $3,127
39 Added 4.67%
874 $46,000
Q1 2024

May 01, 2024

BUY
$17.4 - $94.5 $9,309 - $50,557
535 Added 178.33%
835 $68,000
Q2 2023

Aug 15, 2023

BUY
$14.84 - $24.79 $1,484 - $2,479
100 Added 50.0%
300 $4,000
Q1 2023

May 04, 2023

BUY
$8.08 - $17.33 $1,616 - $3,465
200 New
200 $3,000

Others Institutions Holding VKTX

About Viking Therapeutics, Inc.


  • Ticker VKTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,688,496
  • Market Cap $5.05B
  • Description
  • Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...
More about VKTX
Track This Portfolio

Track Parkside Financial Bank & Trust Portfolio

Follow Parkside Financial Bank & Trust and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Parkside Financial Bank & Trust, based on Form 13F filings with the SEC.

News

Stay updated on Parkside Financial Bank & Trust with notifications on news.